Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells

Molecular and Cellular Endocrinology

Volumn 419, Issue , 2016, Pages 113-123

  Jeon, Min Ji ^a   Kim, Won Gu ^a   Lim, Seonhee ^b   Choi, Hyun Jeung ^b   Sim, Soyoung ^b   Kim, Tae Yong ^a   Shong, Young Kee ^a   Kim, Won Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Institute for Life Sciences   (South Korea)

Author keywords

Alpha lipoic acid; Epithelial mesenchymal transition; Transforming growth factor beta

Indexed keywords

BETA CATENIN; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; SMAD2 PROTEIN; THIOCTIC ACID; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; THYROID CANCER; THYROID CANCER CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; SIGNAL TRANSDUCTION; THIOCTIC ACID; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949579837     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.10.005     Document Type: Article

References (36)

1. American Thyroid Association Guidelines Taskforce on Thyroid, N., Differentiated Thyroid, C., Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., McIver B., Pacini F., Schlumberger M., Sherman S.I., Steward D.L., Tuttle R.M. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
2. Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J., Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell. Biol. 2000, 2:84-89.
3. Brose M.S., Nutting C.M., Jarzab B., Elisei R., Siena S., Bastholt L., de la Fouchardiere C., Pacini F., Paschke R., Shong Y.K., Sherman S.I., Smit J.W., Chung J., Kappeler C., Pena C., Molnar I., Schlumberger M.J., investigators, D. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014, 384:319-328.
4. Cho Y.S., Lee J., Lee T.H., Lee E.Y., Lee K.U., Park J.Y., Moon H.B. alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Allergy Clin. Immunol. 2004, 114:429-435.
5. Choi H.J., Kim T.Y., Chung N., Yim J.H., Kim W.G., Kim J.A., Kim W.B., Shong Y.K. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. J. Endocrinol. 2011, 211:79-85.
6. Choi H.J., Kim T.Y., Ruiz-Llorente S., Jeon M.J., Han J.M., Kim W.G., Shong Y.K., Kim W.B. Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line. Nucl. Med. Biol. 2012, 39:1275-1280.
7. Davis F.M., Stewart T.A., Thompson E.W., Monteith G.R. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol. Sci. 2014, 35:479-488.
8. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., Caillou B., Ricard M., Lumbroso J.D., De Vathaire F., Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 2006, 91:2892-2899.
9. Eloy C., Santos J., Cameselle-Teijeiro J., Soares P., Sobrinho-Simoes M. TGF-beta/smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch. 2012, 460:587-600.
10. Faustino A., Couto J.P., Populo H., Rocha A.S., Pardal F., Cameselle-Teijeiro J.M., Lopes J.M., Sobrinho-Simoes M., Soares P. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2012, 97:E1139-E1149.
11. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell. Biol. 2012, 13:251-262.
12. Haugen B.R., Sherman S.I. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr. Rev. 2013, 34:439-455.
13. Kilfoy B.A., Zheng T., Holford T.R., Han X., Ward M.H., Sjodin A., Zhang Y., Bai Y., Zhu C., Guo G.L., Rothman N., Zhang Y. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009, 20:525-531.
14. Kim I., He Y.Y. Targeting the AMP-activated protein kinase for cancer prevention and therapy. Front. Oncol. 2013, 3:175.
15. Kim M.S., Park J.Y., Namkoong C., Jang P.G., Ryu J.W., Song H.S., Yun J.Y., Namgoong I.S., Ha J., Park I.S., Lee I.K., Viollet B., Youn J.H., Lee H.K., Lee K.U. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med. 2004, 10:727-733.
16. Kim W.G., Zhu X., Kim D.W., Zhang L., Kebebew E., Cheng S.Y. Reactivation of the silenced thyroid hormone receptor beta gene expression delays thyroid tumor progression. Endocrinology 2013, 154:25-35.
17. Kim T.Y., Kim W.G., Kim W.B., Shong Y.K. Current status and future perspectives in differentiated thyroid Cancer. Endocrinol. Metab. 2014, 29:217-225.
18. Kim W.G., Zhao L., Kim D.W., Willingham M.C., Cheng S.Y. Inhibition of tumorigenesis by the thyroid hormone receptor beta in xenograft models. Thyroid 2014, 24:260-269.
19. Kim J.G. Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma. Endocrinol. Metab. 2014, 29:211-216.
20. Knauf J.A., Sartor M.A., Medvedovic M., Lundsmith E., Ryder M., Salzano M., Nikiforov Y.E., Giordano T.J., Ghossein R.A., Fagin J.A. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 2011, 30:3153-3162.
21. Lee Y., Naseem R.H., Park B.H., Garry D.J., Richardson J.A., Schaffer J.E., Unger R.H. Alpha-lipoic acid prevents lipotoxic cardiomyopathy in acyl CoA-synthase transgenic mice. Biochem. Biophys. Res. Commun. 2006, 344:446-452.
22. Lee S.J., Kang J.G., Ryu O.H., Kim C.S., Ihm S.H., Choi M.G., Yoo H.J., Kim D.S., Kim T.W. Effects of alpha-lipoic acid on transforming growth factor beta1-p38 mitogen-activated protein kinase-fibronectin pathway in diabetic nephropathy. Metabolism 2009, 58:616-623.
23. Min A.K., Kim M.K., Seo H.Y., Kim H.S., Jang B.K., Hwang J.S., Choi H.S., Lee K.U., Park K.G., Lee I.K. Alpha-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-beta signaling pathway. Biochem. Biophys. Res. Commun. 2010, 393:536-541.
24. Park K.G., Min A.K., Koh E.H., Kim H.S., Kim M.O., Park H.S., Kim Y.D., Yoon T.S., Jang B.K., Hwang J.S., Kim J.B., Choi H.S., Park J.Y., Lee I.K., Lee K.U. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology 2008, 48:1477-1486.
25. Puisieux A., Brabletz T., Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol. 2014, 16:488-494.
26. Riesco-Eizaguirre G., Rodriguez I., De la Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009, 69:8317-8325.
27. Rosell R., Bivona T.G., Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013, 382:720-731.
28. Sanchez-Tillo E., Liu Y., de Barrios O., Siles L., Fanlo L., Cuatrecasas M., Darling D.S., Dean D.C., Castells A., Postigo A. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell. Mol. Life Sci. 2012, 69:3429-3456.
29. Shoup M., Stojadinovic A., Nissan A., Ghossein R.A., Freedman S., Brennan M.F., Shah J.P., Shaha A.R. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J. Am. Coll. Surg. 2003, 197:191-197.
30. Song K.H., Lee W.J., Koh J.M., Kim H.S., Youn J.Y., Park H.S., Koh E.H., Kim M.S., Youn J.H., Lee K.U., Park J.Y. Alpha-lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. Biochem. Biophys. Res. Commun. 2005, 326:197-202.
31. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
32. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 2013, 13:184-199.
33. Xu K., Liu P., Wei W. mTOR signaling in tumorigenesis. Biochim. Biophys. Acta 2014, 1846:638-654.
34. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
35. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.
36. Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schutte K., Gries F.A. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995, 38:1425-1433.